Clinical Trials Browser

Phase 2 × spartalizumab × 1 year × Clear all

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07403136 2026-04-15

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

Phase 2 Suspended

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

Carcinoma, Renal Cell

NCT03983057 2026-02-11

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT04080804 2026-02-09

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharangeal Cancer

NCT07381309 2026-02-02

VVSHIP

Phase 2 Not yet recruiting

Gastrointestinal

CRC

NCT06468280 2026-01-21

ROSETTE

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06475300 2026-01-21

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2 Recruiting

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06493240 2025-11-25

NLCCRIT-LARC

Phase 2 Completed

Gastrointestinal

Locally Advanced Rectal Cancer

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT06008054 2025-09-26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07053150 2025-07-08

CCGLC-018

Phase 2 Not yet recruiting

Advanced Digestive System Tumor

NCT06728657 2025-06-18

TORCH-G

Phase 2 Suspended

Gastrointestinal

Stomach Adenocarcinoma

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT04821765 2025-05-30

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT06908031 2025-05-14

CRIT

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06437509 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06471205 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms